Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebril in CAA-related Lobar Hemorrhage
NCT00056238Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tramiprosate in cerebral amyloid angiopathy (CAA) (3 arms), sponsored by GSK. Primary endpoints: Safety and Tolerability at 12 weeks and Pharmacokinetics at 12 weeks. Started Feb 2003; status: completed.
02
Drugs
tramiprosate
03
Conditions
cerebral amyloid angiopathy (CAA)
Beyond the preview
Go deeper on NCT00056238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056238.